Chimerix Inc. (NASDAQ:CMRX) shares were up 2.4% on Thursday . The company traded as high as $4.27 and last traded at $4.20, with a volume of 293,175 shares changing hands. The stock had previously closed at $4.10.

A number of research analysts have weighed in on CMRX shares. FBR & Co reissued a “hold” rating on shares of Chimerix in a report on Tuesday, May 10th. Zacks Investment Research raised Chimerix from a “hold” rating to a “buy” rating and set a $5.25 target price on the stock in a report on Wednesday, May 11th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $16.98.

The firm has a 50-day moving average of $4.08 and a 200 day moving average of $5.55. The firm’s market cap is $190.40 million.

Chimerix (NASDAQ:CMRX) last issued its quarterly earnings data on Monday, May 9th. The biopharmaceutical company reported ($0.57) earnings per share for the quarter, topping the consensus estimate of ($0.66) by $0.09. The business earned $1.20 million during the quarter, compared to analysts’ expectations of $2.79 million. Analysts predict that Chimerix Inc. will post ($2.06) earnings per share for the current year.

In other news, Director Ernest Mario purchased 10,000 shares of the stock in a transaction dated Friday, May 13th. The stock was acquired at an average cost of $4.53 per share, for a total transaction of $45,300.00. Following the completion of the transaction, the director now directly owns 331,440 shares in the company, valued at approximately $1,501,423.20. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO M Michelle Berrey purchased 13,188 shares of the stock in a transaction dated Friday, June 24th. The shares were purchased at an average price of $3.69 per share, with a total value of $48,663.72. Following the completion of the transaction, the chief executive officer now owns 258,821 shares of the company’s stock, valued at $955,049.49. The disclosure for this purchase can be found here.

Several hedge funds recently made changes to their positions in CMRX. Morgan Stanley boosted its stake in shares of Chimerix by 96.7% in the fourth quarter. Morgan Stanley now owns 187,163 shares of the biopharmaceutical company’s stock valued at $1,674,000 after buying an additional 92,005 shares during the last quarter. Trexquant Investment LP boosted its stake in shares of Chimerix by 453.5% in the fourth quarter. Trexquant Investment LP now owns 131,184 shares of the biopharmaceutical company’s stock valued at $1,174,000 after buying an additional 107,484 shares during the last quarter. Finally, Jennison Associates LLC boosted its stake in shares of Chimerix by 67.9% in the fourth quarter. Jennison Associates LLC now owns 1,273,779 shares of the biopharmaceutical company’s stock valued at $11,400,000 after buying an additional 515,029 shares during the last quarter.

Chimerix, Inc a biopharmaceutical company dedicated to discovering, developing and commercializing oral antivirals. The Company’s lipid conjugate technology has developed its lead compound, brincidofovir (BCV, CMX001), which is in Phase III clinical development. It is clinical-stage nucleotide analog lipid-conjugate which has demonstrated potent antiviral activity and safety in convenient, orally administered dosing regimens.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.